The Radiopharmaceuticals Division is committed to fulfilling the following mandates:
1. Production, Radiochemical Processing and Supply of Reactor Produced Radionuclides:
Irradiation of targets for production of various radionuclides, radiochemical processing to obtain the irradiated targets in desired chemical form and supplying the radiochemicals to users in Health-care, Industry, Agriculture and research through BRIT.
2. Research, Development, Demonstration and Deployment of State-of-the-art Radiopharmaceuticals:
Research and Development on radiopharmaceuticals with rigorous radiochemical studies and biological evaluation to formulate potential new products for clinical applications. Demonstration and Deployment of the developed radiopharmaceuticals in human health-care in collaboration with various Nuclear Medicine Centers and Hospitals.
3. Production and Supply of Sealed Sources:
Tiny sealed radioactive sources; to be used either as reference sources or for the treatment of cancers (for brachytherapy) are prepared and supplied to various users in Industry and Hospitals.
Malignant tumors aggressively stimulate the formation of new blood vessels to feed the growing tumor mass. Arginylglycylaspartic acid (RGD) is known to bind with the new vasculature. Thus, a technetium-99m labeled form of RGD can detect / image growing malignant tumors of several origins and help in the prognosis/staging of such tumors, which makes it a very useful radiotracer in nuclear medicine.
This is a yttrium-90 labeled form of Hydroxyapatite (Pentacalcium hydroxide triphosphate), a locally applied particulate radiopharmaceutical which has palliative / therapeutic application. It is used for symptomatic pain management of rheumatoid arthritis (RA) patients by administration in the affected synovial joints, minimizing the need for steroid medication with the accompanying side-effects. The greater beta-energy of yttrium-90 allows for more effective pain relief in larger joints like the knee.
This is a lutetium-177 labeled form of Hydroxyapatite (Pentacalcium hydroxide triphosphate), a locally applied particulate radiopharmaceutical which has palliative / therapeutic application. It is used for symptomatic pain management of rheumatoid arthritis (RA) patients by administration in the affected synovial joints, minimizing the need for steroid medication with the accompanying side-effects. The longer decay half-life of lutetium-177 allows for logistical advantage in transport to nuclear medicine therapy centers in remote regions.
This is a lutetium-177 labeled form of DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid), which has palliative / therapeutic application in cancer. It is used for pain reduction and management of bone metastases of cancers of multiple origins, helping to improve the quality of life of patients for the period of survival. The longer decay half-life of lutetium-177 allows for logistical advantage in transport to nuclear medicine therapy centers in remote regions.
This is a rhenium-188 labeled form of Diethyl Dithiocarbamate (DEDC), a lipophilic complex which is then incorporated into lipiodol, a mixture of iodinated esters of fatty acids. The resultant formulation has therapeutic application. It is used for Selective Internal Radiation Therapy (SIRT) of liver cancer by the procedure known as Trans-arterial Radio-embolization (TARE). It has advantageous properties for TARE and is useful in nuclear medicine centers or centralized radiopharmacies that possess radionuclide generator for rhenium-188.
This is a rhenium-188 labeled form of Hydroxyethyl diphosphonate (HEDP), which has palliative / therapeutic application in cancer. It is used for pain reduction and management of bone metastases of cancers of multiple origins, helping to improve the quality of life of patients for the period of survival.
This is an iodine-131 labeled form of lipiodol, a mixture of iodinated esters of fatty acids, which has therapeutic application. It is used for Selective Internal Radiation Therapy (SIRT) of liver cancer by the procedure known as Trans-arterial Radio-embolization.
This is a technetium-99m labeled complex of ubiquicidin, a peptide that specifically binds with bacterial cell wall structures, useful in nuclear medicine as a radiotracer for detection/imaging of deep-seated infections.
This is a gallium-68 labeled somatostatin analog, useful in nuclear medicine as a radiotracer for positron emission tomography (PET) imaging of neuroendocrine tumors.
This is a technetium-99m labeled myocardial perfusion radiotracer, useful in nuclear medicine for detection/imaging of cardiac perfusion abnormalities like ischemia or infarct.
This is a technetium-99m labeled somatostatin analog, useful in nuclear medicine as a radiotracer for detection/imaging of neuroendocrine tumors.